#None #Washington, D.C. #Medtronic #Evolut TAVR #SMART Trial

Evolving Cardiac Care: The SMART Trial's Promising Two-Year Results for Evolut TAVR System

The SMART Trial, officially known as the SMall Annuli Randomized To Evolut or SAPIEN (SMART) study, has reached a significant milestone as it unveils two-year outcomes that bolster the case for the Evolut TAVR (Transcatheter Aortic Valve Replacement) system. Spearheaded by Medtronic plc, this robust trial digs into the complex dynamics of heart valve replacements in patients grappling with aortic stenosis and small annuli. The findings were shared at the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., marking a pivotal moment in cardiac health innovation.

What is the SMART Trial?

The SMART Trial stands out as the largest international comparative study focusing on TAVR, primarily enrolling female patients. With a total of 716 participants—87% of whom were women—the trial examined patients across more than 80 sites worldwide. Participants had a specific profile: they suffered from symptomatic severe aortic stenosis and possessed a small aortic annulus area of ≤430 mm as determined via computed tomography.

Key Findings from the Two-Year Results

The two-year data reveals comparable composite outcomes regarding mortality, disabling strokes, and hospitalizations for heart failure between the Evolut TAVR and its competitor, the SAPIEN valve. However, when it comes to valve performance, the Evolut system continues to demonstrate a significant edge. Notables from the SMART Trial include:

• - Bioprosthetic Valve Dysfunction (BVD): Evolut TAVR showcased significantly lower BVD rates, minimizing the risk of adverse outcomes compared to SAPIEN TAVR.
• - Prosthetic Valve Thrombosis: The study recorded five times fewer incidents of prosthetic valve thrombosis (p=0.0048).
• - Hemodynamic Structural Valve Dysfunction: It reported nine times less hemodynamic structural valve dysfunction, defined by mean gradients of ≥ 20mmHg (p<0.001).

Dr. Howard C. Herrmann, a leading investigator of the trial from the Perelman School of Medicine at the University of Pennsylvania, emphasized that the continued superior performance of the Evolut valve can significantly inform and personalize treatment plans for patients vulnerable to inadequate cardiac support.

Implications for Patients

Aortic stenosis, affecting about 1.5 million people in the U.S., poses fatal risks if untreated, and these latest results highlight the importance of tailored valve selections for those with small aortic annuli. Dr. Kendra J. Grubb, Chief Medical Officer at Medtronic, reiterated that the persistence of superior valve performance from the Evolut system indicates promising long-term outcomes, which will remain under observation for up to five years.

In essence, the SMART Trial acts as a beacon of hope for patients with aortic stenosis and small annuli, where the use of the Evolut TAVR system can optimize their cardiac care pathway. With strong evidence supporting its effectiveness, healthcare professionals are now better equipped to make informed decisions that prioritize patient safety and health outcomes.

The Future of Cardiac Health

As cardiac technologies continue to advance, the findings from the SMART Trial underscore the need for continuous innovation in valve designs tailored to patient physiology. Medtronic's commitment to enhancing patient care is evident in its aggressive pursuit of groundbreaking solutions to tackle heart disease. With the SMART Trial results, patients and healthcare providers alike can embark on a journey towards improved cardiac health, based on empirical evidence of valve performance efficacy.

• ---

For more information, visit Medtronic's official site and stay updated on developments in TAVR technology and ongoing clinical studies.